Bayer AG (BAYRY) Q3 2025 Earnings Call Highlights: Strong EPS Growth Amid Market Challenges [Yahoo! Finance]
BAYER AG S/ADR (BAYRY)
NASDAQ:AMEX Investor Relations:
investor.bayer.com
Company Research
Source: Yahoo! Finance
Net Sales Growth: 1% increase in currency and portfolio adjusted terms. EBITDA Before Special Items: 1.5 billion, up 21% from the prior year. Net Financial Debt: Decreased by 600 million to 32.7 billion. Crop Science Sales: 3.9 billion, up 1% year-over-year. Pharmaceuticals Sales: 4.3 billion, with Nubecka up 60% and Correia up nearly 80% year-over-year. Consumer Health Sales Growth: 2% in Q3. EBITDA Margin (Pharmaceuticals): EBITDA Margin (Consumer Health): Year-to-Date EBITDA Margin: Litigation Provisions: 934 million in special items for litigation-related provisions. Warning! GuruFocus has detected 4 Warning Sign with BAYRY. Is BAYRY fairly valued? Test your thesis with our free DCF calculator. Release Date: November 12, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript Positive Points Bayer AG ( BAYRY ) reported a 7% increase in core EPS to 4.29, indicating strong profitability. Free cash flow
Show less
Read more
Impact Snapshot
Event Time:
BAYRY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BAYRY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BAYRY alerts
High impacting BAYER AG S/ADR news events
Weekly update
A roundup of the hottest topics
BAYRY
News
- Study that said glyphosate herbicide is safe retracted 25 years after publication [Yahoo! Finance Canada]Yahoo! Finance Canada
- Bayer Starts Phase IIa Study for Treatment of Patients With Alport SyndromeBusiness Wire
- Taboo no more: Leaders gather to discuss women's health [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Trump administration backs Bayer as Roundup fight moves toward Supreme Court [FOX Business Network]FOX Business Network
- RSNA25: Pediatric Study for Bayer's Investigational MRI Contrast Agent Gadoquatrane Meets Primary and Secondary EndpointsBusiness Wire